The Phase IIb
study will aim at demonstrating efficacy of nangibotide and bring a clinically relevant proof of clinical activity in septic shock patients.
This three-year Phase IIB
Bridge SBIR (Small Business Innovation Research) federal funds was granted by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH) under Award No.
The company expects to report completion of recruitment by mid-2014 and 12-week topline data from the Phase IIb
programme in the fourth quarter of 2014.
The phase IIb
clinical study is presented as a poster.
Patients for the Phase IIb
study will be selected based on having genotype 1 chronic HCV and having failed to respond to pegylated alpha interferon plus ribavirin therapy (non-responders).
As a result, GSK has decided to terminate Phase IIB
studies in HIV-positive patients who have never taken any AIDS drug.
uniQure announced initial clinical data in patients treated in the company's Phase IIb
dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant, for the treatment of patients with severe and moderately severe hemophilia B.
M2 EQUITYBITES-August 22, 2018-CytoSorbents wins up to USD3m SBIR Phase IIB
Bridge funding for its HemoDefend blood transfusion filter
The $3.3m total raised is projected to provide funding to complete implants in the Phase IIb
clinical trial of NTCELL for Parkinsons disease which commenced on 24 March.
(SeeNews) - Jun 13, 2013 - Belgian biopharmaceuticals company UCB (EBR:UCB) announced today new data from an open-label extension of its Phase IIb
study with epratuzumab for the treatment of systemic lupus erythematosus (SLE).
20 May 2011 - Swedish pharma company Medivir AB (STO:MVIR B) announced today positive 48-week interim data from a Phase IIb
clinical trial with candidate drug TMC435 for the treatment of hepatitis C virus (HCV) genotype-1 (G1).
Tokyo, Japan, Sept 6, 2005 - (JCNN) - Sosei, a Japanese biopharmaceutical company, announced on September 5 that its wholly owned UK subsidiary Arakis has started a phase IIb
dose-ranging study of AD 452, an investigational drug for the treatment of rheumatoid arthritis (RA).